Intravitreal Methotrexate (IMTX) for Treatment of Uveitis

Alay S. Banker, MD; Rohan Chauhan, DO

Purpose: To evaluate efficacy of intravitreal-methotrexate(IMTX) in uveitis resistant/intolerant to conventional treatments.

Methods: Prospective study of IMTX(400microg/0.1ml) in15 eyes(13patients) with intermediate uveitis. Outcome measures included anatomic, visual improvement and change in central macular thickness(CMT).

Results: Inflammation resolved in all(100%) eyes for varying periods upto 6 months. 3 eyes needed repeat injection after 3 months, only 3 patients needed additional therapy. Mean vision improved from 0.606 to 0.437 LogMAR at 6 months. CMT decreased from 363.06 to 348.5 at 6 months. No eyes developed glaucoma/cataract.

Conclusions: In patients with uveitis, IMTX can improve vision, reduce CME and may allow reduction of immunosuppressive therapy.